Get started

Financials · AUTL

Autolus Therapeutics plc (AUTL) financials

For the twelve months ended Jun 30, 2026, Autolus Therapeutics plc reported $117.39M of revenue and -$280.16M of net income.

Revenue, TTM
$117.39M
Revenue growth, YoY
+292.2%
Net income, TTM
-$280.16M
Net margin
-238.7%
Free cash flow, TTM
-$234.50M
EPS, diluted, TTM
-$1.06
Cash
$171.41M
P/S
2.99
Market cap
$351.3M
Annual revenue$75.39M
FY2016FY2025
Annual net income-$287.53M
FY2016FY2025
Annual free cash flow-$302.61M
FY2016FY2025

AUTL revenue and earnings growth

AUTL revenueQ2 2026$45.69M

Quarter YoY
+118.4%
QoQ
+74.3%
FY YoY
+644.9%

AUTL revenue was $45.69M in fiscal Q2 2026 (ended Jun 30, 2026), up 118.4% from a year earlier and up 74.3% from the prior quarter. For the full fiscal 2025 it was $75.39M, up 644.9% from fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

AUTL net incomeQ2 2026-$39.11M

AUTL net income was -$39.11M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$47.92M a year earlier. For the full fiscal 2025 it was -$287.53M, compared with -$220.66M in fiscal 2024.

AUTL EPSQ2 2026-$0.15

AUTL diluted EPS was -$0.15 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.18 a year earlier. For the full fiscal 2025 it was -$1.08, compared with -$0.86 in fiscal 2024.

AUTL free cash flowQ2 2026-$25.98M

AUTL free cash flow was -$25.98M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$80.06M a year earlier. For the full fiscal 2025 it was -$302.61M, compared with -$228.35M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Revenue$75.39M$10.12M$1.70M---$2.91M$1.41M$1.69M$1.21M
Cost of revenue$96.37M$11.39M$0-------
Gross profit-$20.98M-$1.27M$1.70M-------
Research and development$117.69M$138.44M$130.48M$117.35M$110.84M$134.89M$105.42M$36.15M$16.01M$10.44M
Selling, general and admin$131.87M$101.72M$46.74M$31.90M$31.86M$34.97M$39.45M$22.79M$9.10M$5.15M
Operating income-$270.54M-$241.43M-$179.70M-$143.41M-$141.05M-$168.15M-$146.06M-$57.53M-$23.42M-
Interest expense$36.67M$9.29M$45.07M$8.90M$1.10M$0$0---
Pre-tax income-$285.56M-$219.13M-$208.40M-$148.57M-$142.04M-$166.26M-$139.01M-$52.03M-$23.38M-$14.33M
Income tax$1.97M$1.53M-$19.0K$272.0K$58.0K-$24.16M-$15.16M-$7.28M-$3.65M-$1.78M
Net income-$287.53M-$220.66M-$208.38M-$148.84M-$142.10M-$142.09M-$123.85M-$44.75M-$19.73M-$12.55M
EPS, basic-$1.08-$0.86-$1.20-$1.57-$1.97-$2.76-$2.88-$1.42-$1.43-$1.26
EPS, diluted-$1.08-$0.86-$1.20-$1.57-$1.97-$2.76-$2.88-$1.42-$1.43-$1.26
Diluted shares266.1M255.2M173.9M95.0M72.1M51.6M43.1M31.6M13.8M9.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Cash and equivalents$104.13M$228.81M$240.34M$382.76M$310.34M$154.09M$211.43M$247.09M$137.07M$28.06M
Receivables$24.02M$15.0K$109.0K$121.0K$0-----
Inventory$33.21M$4.14M$0-------
Current assets$435.92M$660.93M$275.30M$425.77M$346.95M$196.98M$249.26M$259.28M$142.48M-
Total assets$589.07M$782.73M$375.38M$490.27M$405.56M$294.24M$303.53M$273.20M$148.66M-
Current liabilities$73.44M$60.74M$44.74M$46.37M$28.55M$33.63M$24.98M$17.14M$5.03M-
Long-term debt------$0$380.0K$763.0K-
Total debt------$0$380.0K$763.0K-
Total liabilities$410.94M$355.40M$263.91M$191.60M$92.24M$84.20M$48.69M$17.74M$6.06M-
Shareholders' equity$178.13M$427.32M$111.47M$298.67M$313.32M$210.03M$254.84M$255.47M$142.60M$30.69M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Operating cash flow-$283.57M-$206.27M-$145.59M-$112.31M-$117.86M-$117.76M-$101.48M-$31.54M-$16.36M-$9.85M
Capital expenditures$19.04M$22.07M$10.99M$10.84M$8.86M$14.68M$18.34M$9.12M$2.88M$1.85M
Free cash flow-$302.61M-$228.35M-$156.57M-$123.15M-$126.72M-$132.44M-$119.83M-$40.66M-$19.24M-$11.70M
Investing cash flow$158.46M-$394.55M-$10.99M-$10.84M-$8.86M-$14.68M-$18.67M-$9.53M-$2.88M-$1.85M
Financing cash flow-$4.34M$589.55M-$883.0K$223.61M$284.06M$74.42M$108.86M$156.92M$127.69M$32.22M
Depreciation and amortization$8.30M$7.55M$6.57M$7.42M$8.46M$5.66M$4.61M---

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Sep 30, 2018
FY2017
Sep 30, 2017
FY2016
Sep 30, 2016
Revenue growth, YoY644.9%496.0%----106.7%-16.9%39.7%-
Gross margin-27.8%-12.5%100.0%-------
Operating margin-358.9%-2385.6%-10583.1%----5022.8%-4089.1%-1383.2%-
Net margin-381.4%-2180.5%-12272.3%----4258.9%-3180.6%-1165.2%-1035.5%
Free cash flow margin-401.4%-2256.4%-9221.0%----4120.5%-2889.6%-1136.2%-965.7%
Return on equity-161.4%-51.6%-186.9%-49.8%-45.4%-67.7%-48.6%-17.5%-13.8%-40.9%
Return on assets-48.8%-28.2%-55.5%-30.4%-35.0%-48.3%-40.8%-16.4%-13.3%-
Current ratio5.9410.886.159.1812.155.869.9815.1328.31-
Debt to equity------0.000.000.01-

Source: XBRL data Autolus Therapeutics plc files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

AUTL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
AUTL$117.39M+292.2%-$280.16M-238.7%$351.3M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$211.94B
MRNA$2.52B+13.1%-$2.79B-110.5%$101.49B
ARGX$4.25B+88.6%$1.29B30.4%$60.30B
RVMD$0--$1.13B-$41.76B
BIIB$10.30B+2.3%$347.50M3.4%$37.44B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.91B
EXEL$2.50B+9.1%$885.14M35.5%$17.22B

AUTL FAQ

9 questions
  • What is AUTL revenue?
    Autolus Therapeutics plc (AUTL) reported $117.39M of revenue for the twelve months ended Jun 30, 2026. That is up 292.2% from the year before. Revenue for fiscal 2025 was $75.39M.
  • Is AUTL profitable?
    No. Autolus Therapeutics plc reported a net loss of $280.16M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does AUTL have?
    Autolus Therapeutics plc reported $171.41M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is AUTL revenue growing?
    Autolus Therapeutics plc's revenue changed +644.9% in fiscal 2025, to $75.39M.
  • What is AUTL gross margin?
    Autolus Therapeutics plc's gross profit was $18.38M on $117.39M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 15.7%.
  • What is AUTL free cash flow?
    Autolus Therapeutics plc generated -$234.50M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$225.61M less capital expenditures.
  • What is AUTL earnings per share?
    Diluted earnings per share were -$1.06 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did AUTL last report financial results?
    The latest statements here come from Autolus Therapeutics plc's 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this AUTL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Autolus Therapeutics plc files with the SEC. It is provided for information only and is not investment advice.